Product Description
Mechanisms of Action: Hyaluronidase Analogue
Novel Mechanism: Yes
Modality: N/A
Route of Administration: Rectal,Vaginal
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Russia
Approved Indications: None
Known Adverse Events: None
Company: NPO Petrovax
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Russia
Active Clinical Trial Count: 1
Highest Development Phases
Phase 3: Lung Diseases, Interstitial|Polymyositis|Post Acute COVID-19 Syndrome
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| Long-Cov-III-21 | P3 |
Completed |
Post Acute COVID-19 Syndrome|Lung Diseases, Interstitial|Polymyositis |
2023-12-31 |
39% |